Table 1 Patient demographics and baseline characteristicsa,b

From: Ocular hypotensive effect of fixed-combination brinzolamide/brimonidine adjunctive to a prostaglandin analog: a randomized clinical trial

 

BBFC+PGA (n=88)

Vehicle+PGA (n=94)

Age, years

 Mean±SD

65.5±9.4

64.7±9.6

 Range

36–86

30–87

Sex, n (%)

 Female

53 (60.2)

63 (67.0)

 Male

35 (39.8)

31 (33.0)

Race, n (%)

 White

61 (69.3)

55 (58.5)

 Black or African American

25 (28.4)

39 (41.5)

 Asian

2 (2.3)

0

Diagnosis, n (%)

 Open-angle glaucoma

72 (81.8)

71 (75.5)

 Ocular hypertension

15 (17.0)

19 (20.2)

 Open-angle glaucoma with pseudoexfoliation

0

1 (1.1)

 Open-angle glaucoma with pigment dispersion

1 (1.1)

3 (3.2)

PGA monotherapy, n (%)

 Latanoprost 0.005%

33 (37.5)

37 (39.4)

 Bimatoprost 0.01%

31 (35.2)

33 (35.1)

 Travoprost 0.004%

24 (27.3)

24 (25.5)

Diurnal intraocular pressure, mm Hg

 Mean±SD

22.7±2.1

22.4±2.8

 Range

18.0–27.8

16.0–30.5

  1. Abbreviations: BBFC, fixed-combination brinzolamide 1%/brimonidine 0.2%; PGA, prostaglandin analog; SD, standard deviation.
  2. aPercentages may not add up to 100 because of rounding off.
  3. bNo meaningful differences were observed between treatment groups for any demographic characteristic.